Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–1379
View Full Paper
Ask AI
Bookmark
Share
Key Points
To clarify properties of glucose-lowering agents and guide treatment choices for individual patients with type 2 diabetes.
Correction of footnotes in Table 1 regarding vildagliptin
Emphasis on patient-centered approaches for diabetes management
Vildagliptin's footnote corrected to indicate it is not licensed in the U.S.
Updates reflected in the online version to ensure accurate information for clinicians
Discussion
No takes yet. Share an insight, caveat, or question.
Implication
Position statement addresses glucose-lowering agents in type 2 diabetes, ensuring accurate treatment guidance.